WallStreetZenWallStreetZen

NASDAQ: CYCN
Cyclerion Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their CYCN stock forecasts and price targets.

Forecast return on equity

Is CYCN forecast to generate an efficient return?

Company
-34.42%
Industry
54.76%
Market
354.04%
CYCN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CYCN forecast to generate an efficient return on assets?

Company
-31.52%
Industry
15.04%
CYCN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CYCN earnings per share forecast

What is CYCN's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.92
Avg 2 year Forecast
-$0.84

CYCN revenue forecast

What is CYCN's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0-100%
Avg 2 year Forecast
$0.0-100%
CYCN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CYCN revenue growth forecast

How is CYCN forecast to perform vs Biotechnology companies and vs the US market?

Company
-100%
Industry
138.44%
Market
1,349%
CYCN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CYCN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CYCN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CYCN$1.30N/AN/A
PCSA$2.28N/AN/A
GTBP$0.47N/AN/A
BGMS$1.01N/AN/A
MBRX$2.38$22.00+824.37%Buy
View Top Biotech Stocks

Cyclerion Therapeutics Stock Forecast FAQ

What is CYCN's earnings growth forecast for 2026-2027?

(NASDAQ: CYCN) Cyclerion Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 101.41%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 3,299.62%.

Cyclerion Therapeutics's earnings in 2026 is -$2,199,000.On average, 3 Wall Street analysts forecast CYCN's earnings for 2026 to be -$3,603,438, with the lowest CYCN earnings forecast at -$3,462,127, and the highest CYCN earnings forecast at -$3,709,422.

In 2027, CYCN is forecast to generate -$3,283,133 in earnings, with the lowest earnings forecast at -$3,154,382 and the highest earnings forecast at -$3,379,695.

If you're new to stock investing, here's how to buy Cyclerion Therapeutics stock.

What is CYCN's revenue growth forecast for 2026-2027?

(NASDAQ: CYCN) Cyclerion Therapeutics's forecast annual revenue growth rate of -100% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 138.44%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,349%.

Cyclerion Therapeutics's revenue in 2026 is $2,855,000.On average, 3 Wall Street analysts forecast CYCN's revenue for 2026 to be $0, with the lowest CYCN revenue forecast at $0, and the highest CYCN revenue forecast at $0.

In 2027, CYCN is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is CYCN's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: CYCN) forecast ROA is -31.52%, which is lower than the forecast US Biotechnology industry average of 15.04%.

What is CYCN's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: CYCN) Cyclerion Therapeutics's current Earnings Per Share (EPS) is -$0.75. On average, analysts forecast that CYCN's EPS will be -$0.92 for 2026, with the lowest EPS forecast at -$0.88, and the highest EPS forecast at -$0.95. In 2027, CYCN's EPS is forecast to hit -$0.84 (min: -$0.80, max: -$0.86).

What is CYCN's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: CYCN) forecast ROE is -34.42%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.